Hepatorenal syndrome

##plugins.themes.academic_pro.article.sidebar##

Published Dec 19, 2011
Download
pdf
Vol. 89 No. (2011): Issue Dec 2011

##plugins.themes.academic_pro.article.main##

N Ben Chaabane
W Melki
Olfa Hellara
Leila Safer
Fethia BDIOUI
Hammouda Saffar

Abstract

Background: Hepatorenal syndrome (HRS) is a particular form of functional renal failure which may develop in patients with liver cirrhosis. Recent advances in the understanding of the biology of vasoactive mediators and the physiology of microcirculation have allowed to better anticipate its pathophysiological mechanisms.
Aim: To review new advances in the knowledge of epidemiology, diagnosis criteria, pathophysiological mechanisms and treatment of HRS.
Methods: Review of literature using medical data bases (Medline) with the following key words: hepatorenal syndrome, pathophysiology, medical treatment, MARS, liver transplantation.
Results: During the course of cirrhosis, portal hypertension leads to splanchnic and systemic vasodilation, responsible for a reduction of effective arteriel blood volume. As a result, a state of intense renal vasoconstriction develops, leading to renal failure in the absence of any organic renal disease. At this stage, liver transplantation is the only definitive therapy able to reverse renal dysfunction.
Pharmacologic and radiologic therapy is aimed at improving renal function to enable patients to survive until transplantation is possible. These therapies are based on vasoconstrictor drugs associated with intravenous albumin infusion and transjugular intrahepatic portosystemic shunt (TIPS). They improve circulatory function, normalize serum creatinine and may improve survival.
Conclusion: Simple measures have been shown to reduce the risk of HRS in cirrhotic patients including the plasma volume expansion with albumin in patients with spontaneous bacterial peritonitis and optimal fluid management in patients undergoing large volume paracentesis.

Keywords:

Hepatorenal syndrome

##plugins.themes.academic_pro.article.details##

References

  1. Moore KP, Wong F, Gines P et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003; 38 :258-66.
  2. Cardenas A, Gines P. Hepatorenal syndrome. Clin Liver Dis. 2006; 10 :371-85.
  3. Zaza S, Bonny O, Liaudet L. Hepatorenal syndrome in patients with liver cirrhosis. Nephrol Ther. 2005; 1 :174-82.
  4. Arroyo V, Terra C, Gines P. New treatments of hepatorenal syndrome. Semin Liver Dis. 2006; 26 :254-64.
  5. Sargent S, Martin W. Renal dysfunction in liver cirrhosis. Br J Nurs. 2006; 15 :12-6.
  6. Gerbes AL, Gulberg V. Progress in treatment of massive ascites and hepatorenal syndrome. World J Gastroenterol. 2006; 12 :516-9.
  7. Follo A, Llovet JM, Navasa M,et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994; 20 : 1495-501.
  8. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94 :1493-502.
  9. Sort P, Navasa M, Arroyo V, al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999; 341 :403-9.
  10. Bataller R, Gines P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liver Dis. 1997; 17 :233-47
  11. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002; 122 :923-30
  12. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med. 2004; 350 :1646-54.
  13. Tito L, Gines P, Arroyo V, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology1990; 98: 146-5.
  14. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999; 29 :1655-61
  15. Consensus conference - Complications of portal hypertension in adults: consensus text. Gastroenterol Clin Biol. 2004 Feb; 28 : 135-52
  16. Mathurin P, Mendenhall CL, Carithers RL Jr et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol. 2002; 36 :480-7
  17. Mathurin P, Abdelnour M, Ramond MJ et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 2003; 38 :1363-9
  18. Gulberg V, Bilzer M, Gerbes AL Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology. 1999 ; 30 :870-5
  19. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology. 1998; 27 : 35-41
  20. Halimi C, Bonnard P, Bernard B et al.. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol. 2002; 14 :153-8.
  21. Ortega R, Gines P, Uriz J et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002; 3: 941- 8
  22. Gluud LL, Kjaer MS, Christensen E Terlipressin for hepatorenal syndrome.Cochrane Database Syst Rev. 2006; 18 :CD005162.
  23. Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999; 29: 1690-7
  24. Duvoux C,Zanditenas D,Hézode C,Chauvat A,Métreau JM,Dhumeaux D. Noradrenaline for treatment of type I hepatorenal syndrome (HRS). A phase II study. Hepatology 2001;34 : 168A.
  25. Holt S, Goodier D, Marley R et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet. 1999; 353 :294-5
  26. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in nontransplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000 ; 47:288-95.
  27. Guevara M, Gines P, Bandi JC et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416-22.
  28. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55-64
  29. Mitzner SR, Stange J, Klammt S et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000;6:277-86.
  30. Restuccia T, Ortega R, Guevara M et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol. 2004; 40:140-6